Filing Analysis
China Pharma Holdings, Inc. has rescinded a securities purchase agreement that was originally entered into on December 12, 2024. The rescission renders the previous agreement void from its inception.
🚩 Red Flags
- Rapid reversal of a material securities transaction (only 11 days between signing and rescission).
- Potential failure of capital raising efforts, which is critical for micro-cap companies.
- Uncertainty regarding the underlying cause of the rescission (e.g., funding failure or dispute).
📋 Key Facts
- The Company and an unnamed Investor reached a rescission agreement on December 23, 2024.
- The rescinded agreement was a securities purchase agreement dated December 12, 2024.
- The previous agreement was disclosed in an 8-K filing on December 13, 2024.
- The rescission makes the original agreement void from the beginning (ab initio).
China Pharma Holdings, Inc. held its annual stockholders' meeting on December 22, 2024, where shareholders approved several key measures including the election of directors and an amendment to effect a reverse stock split.
🚩 Red Flags
- Approval of a reverse stock split is often used to maintain exchange listing requirements (e.g., minimum bid price), which can be a sign of impending delisting risk or extreme share price depreciation.
- The company's voting results for the reverse split show significant 'Votes Against' (233,537) compared to other items, indicating shareholder dissent on this specific structural change.
📋 Key Facts
- Annual Meeting held on December 22, 2024; quorum established with 9,688,133 shares (approx. 52% of outstanding).
- Shareholders approved an amendment to the Articles of Incorporation to effect a reverse stock split.
- The proposed reverse split ratio is between 1:10 and 1:20; Board retains discretion on timing and final ratio.
- Five directors were elected: Zhilin Li, Heung Mei Tsui (non-independent), Gene Michael Bennett, Yingwen Zhang, and Baowen Dong (independent).
- Amendment No. 2 to the 2010 Long-Term Incentive Plan was approved.
- Shareholders approved compensation for named executive officers on an advisory basis.
China Pharma Holdings, Inc. entered into a securities purchase agreement for an at-the-market (ATM) offering of up to $600,000 in common stock with an institutional investor.
🚩 Red Flags
- Extremely short commitment window (less than 20 days), suggesting urgent need for liquidity.
- Low share price floor ($0.15) indicates high volatility and potential dilution risk.
- MFN clause includes retroactive adjustments via convertible notes, which can lead to significant future dilution.
📋 Key Facts
- The offering is an at-the-market (ATM) arrangement with an aggregate price cap of $600,000.
- The commitment period is from December 12, 2024, to December 31, 2024.
- The floor price for shares is set at $0.15 per share.
- Includes a 'Most Favored Nation' (MFN) clause: if the company offers better terms to others within 30 days, those terms apply retroactively to this investor via convertible note issuance.
- The investor has the right to return shares within one business day if market conditions are unfavorable.
China Pharma Holdings, Inc. entered into a Second Amendment to its Convertible Promissory Note with Streeterville Capital, LLC, extending the maturity date and restructuring redemption terms.
🚩 Red Flags
- Restructuring of debt terms suggests liquidity/cash flow constraints to meet previous monthly obligations.
- Significant reduction in monthly redemption requirements (approx. 75% decrease) indicates difficulty meeting original repayment schedules.
- Continued reliance on convertible debt which can lead to significant dilution for existing shareholders.
📋 Key Facts
- The Company extended the maturity date of the existing Convertible Promissory Note to August 19, 2025.
- An extension fee equal to 2% of the outstanding balance was agreed upon.
- Minimum monthly redemption amount reduced from $150,000.00 to $37,182.33.
- The outstanding balance as of May 23, 2024, is $557,735.00 (down from an original issuance of $5,250,000.00 in November 2021).
- Note Holder: Streeterville Capital, LLC.
China Pharma Holdings, Inc. terminated its engagement with BF Borgers CPA PC following an SEC Rule 102(e) Order that denied the firm's privilege to practice before the SEC. The company has appointed Enrome LLP as its new independent registered public accounting firm.
🚩 Red Flags
- Auditor change triggered by SEC disciplinary action (Rule 102(e) Order) against the previous auditor.
- Existing 'going concern' qualification in recent audit reports for FY2023 and FY2022.
- Regulatory risk associated with the sudden loss of a practicing accountant.
📋 Key Facts
- Termination of BF Borgers CPA PC effective May 7, 2024.
- The SEC issued a Rule 102(e) Order against BF Borgers CPA PC on May 3, 2024, barring them from practicing before the SEC.
- Enrome LLP has been appointed as the new independent registered public accounting firm by the audit committee.
- Previous audit reports for fiscal years ended Dec 31, 2023 and 2022 contained a going concern qualification.
China Pharma Holdings, Inc. has been notified by NYSE American that it is back in compliance with listing standards regarding its minimum selling price following a recent reverse stock split. While the non-compliance indicator will be removed, the Exchange warned of immediate delisting risk if the stock trades at abnormally low levels again.
🚩 Red Flags
- Risk of immediate delisting: The Exchange stated there is no cure period if the stock trades at abnormally low levels again.
- History of non-compliance: The company required a reverse split to maintain listing status, indicating significant downward price pressure.
- Potential for recurring volatility/delisting risk.
📋 Key Facts
- Received notification from NYSE American on March 27, 2024, regarding compliance status.
- Company resolved deficiency related to low selling price (Section 1003(f)(v) of the NYSE American Company Guide).
- Compliance was achieved via a 1-for-5 reverse stock split executed on March 6, 2024.
- The 'Below Compliance' (.BC) indicator will be removed from dissemination.
China Pharma Holdings, Inc. announced a 1-for-5 reverse stock split to be effective on March 6, 2024. This action will convert every five shares of common stock into one share of post-split common stock.
🚩 Red Flags
- Reverse stock split (often used to combat delisting notices due to low share price)
- Potential for increased volatility and dilution of shareholder perception
📋 Key Facts
- Reverse split ratio: 1-for-5
- Effective date: Wednesday, March 6, 2024
- Trading to begin on a split-adjusted basis at market open on March 6, 2024
- Pre-split par value: $0.001 per share; Post-split par value: $0.001 per share
China Pharma Holdings, Inc. entered into a Technology Transfer Agreement with Lihua Li for an invention patent related to psoriasis treatment. The transaction involves the issuance of 15 million restricted shares valued at $0.10 per share as part of a $1.50 million acquisition.
🚩 Red Flags
- Related-party transaction: The filing does not explicitly state the relationship between Lihua Li and the company/insiders, but the low share price ($0.10) relative to typical market valuations often signals distress or significant dilution.
- Significant Dilution: Issuance of 15 million shares at a very low price point ($0.10 per share) represents substantial potential dilution for existing shareholders.
- Unregistered Securities: The shares are being issued under Regulation S (offshore transaction) and are not registered under the Securities Act.
📋 Key Facts
- Agreement date: February 2, 2024
- Transferor: Lihua Li (and two designees)
- Asset acquired: Invention patent for a pharmaceutical composition for the treatment of psoriasis
- Total consideration: $1.50 million
- Payment method: Issuance of 15,000,000 restricted shares of common stock at $0.10 per share
- Contingent consideration: 10% of annual net profit from sales for 10 years post-market launch (if profitable)
- The transferor will also provide technical services including R&D and registration support in Haikou, China.